Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check5 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0, signaling a site update. The visible study details remain unchanged.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating an updated page version and likely related internal improvements or bug fixes.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page revision label was updated from v3.6.4 to v3.6.5, indicating a newer version of the page. This update is a metadata increment and does not change visible content.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page's revision indicator was updated from v3.6.3 to v3.6.4, signaling a small update to the page's content or formatting.SummaryDifference0.1%

- Check82 days agoChange DetectedRevision updated from v3.6.0 to v3.6.3, indicating a minor software update to the page's underlying framework. This change does not indicate any visible alterations to the study details or user-facing content based on the provided data.SummaryDifference0.1%

- Check97 days agoChange DetectedThe study page now indicates that enrollment has closed ('No longer looking for participants'). It also adds new sections and headings for user guidance and study details (How to Read a Study Record, Common Questions, How to Join a Study, Intervention/Treatment), reflecting a reorganized information layout.SummaryDifference0.4%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.